Citations (18)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Mohd Wahid, Arshad Jawed, Sajad Ahmad Dar, Raju K Mandal & Shafiul Haque. (2017) Differential pharmacology and clinical utility of sonidegib in advanced basal cell carcinoma. OncoTargets and Therapy 10, pages 515-520.
Read now
Read now
Nicholas J. Collier, Faisal R. Ali & John T. Lear. (2016) The safety and efficacy of sonidegib for the treatment of locally advanced basal cell carcinoma. Expert Review of Anticancer Therapy 16:10, pages 1011-1018.
Read now
Read now
Egle Ramelyte, Valerie C. Amann & Reinhard Dummer. (2016) Sonidegib for the treatment of advanced basal cell carcinoma. Expert Opinion on Pharmacotherapy 17:14, pages 1963-1968.
Read now
Read now
Articles from other publishers (15)
Uffe Høgh Olesen, Gael Clergeaud, Kristoffer Kjærgaard Hendel, Kelvin Yeung, Catharina Margrethe Lerche, Thomas Lars Andresen & Merete Haedersdal. (2020) Enhanced and Sustained Cutaneous Delivery of Vismodegib by Ablative Fractional Laser and Microemulsion Formulation. Journal of Investigative Dermatology 140:10, pages 2051-2059.
Crossref
Crossref
Balaram S. Takale, Ruchita R. Thakore, Fan Yi Kong & Bruce H. Lipshutz. (2019) An environmentally responsible 3-pot, 5-step synthesis of the antitumor agent sonidegib using ppm levels of Pd catalysis in water. Green Chemistry 21:23, pages 6258-6262.
Crossref
Crossref
Assuntina G. Sacco & Gregory A. Daniels. (2019) Adjuvant and Neoadjuvant Treatment of Skin Cancer. Facial Plastic Surgery Clinics of North America 27:1, pages 139-150.
Crossref
Crossref
Andrew C. Flick, Hong X. Ding, Carolyn A. Leverett, Robert E. KyneJr.Jr., Kevin K. -C. Liu, Sarah J. Fink & Christopher J. O’Donnell. (2017) Synthetic Approaches to the New Drugs Approved During 2015. Journal of Medicinal Chemistry 60:15, pages 6480-6515.
Crossref
Crossref
Erik Montagna & Otávio Sérgio Lopes. (2017) Molecular basis of basal cell carcinoma. Anais Brasileiros de Dermatologia 92:4, pages 517-520.
Crossref
Crossref
Heidi J. Einolf, Jocelyn Zhou, Christina Won, Lai Wang & Sam Rebello. (2017) A Physiologically-Based Pharmacokinetic Modeling Approach To Predict Drug–Drug Interactions of Sonidegib (LDE225) with Perpetrators of CYP3A in Cancer Patients. Drug Metabolism and Disposition 45:4, pages 361-374.
Crossref
Crossref
Jocelyn Zhou, Michelle Quinlan, Eunju Hurh & Dalila Sellami. (2016) Exposure-Response Analysis of Sonidegib (LDE225), an Oral Inhibitor of the Hedgehog Signaling Pathway, for Effectiveness and Safety in Patients With Advanced Solid Tumors. The Journal of Clinical Pharmacology 56:11, pages 1406-1415.
Crossref
Crossref
Reinhard Dummer, Alexander Guminski, Ralf Gutzmer, Luc Dirix, Karl D. Lewis, Patrick Combemale, Robert M. Herd, Martin Kaatz, Carmen Loquai, Alexander J. Stratigos, Hans-Joachim Schulze, Ruth Plummer, Sven Gogov, Celine Pallaud, Tingting Yi, Manisha Mone, Anne Lynn S. Chang, Frank Corn?lis, Ragini Kudchadkar, Uwe Trefzer, John T. Lear, Dalila Sellami & Michael R. Migden. (2016) The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma. Journal of the American Academy of Dermatology 75:1, pages 113-125.e5.
Crossref
Crossref
Emilie Lauressergues, Peter Heusler, Fabrice Lestienne, David Troulier, Isabelle Rauly‐Lestienne, Amélie Tourette, Marie‐Christine Ailhaud, Claudie Cathala, Stéphanie Tardif, Delphine Denais‐Laliève, Marie‐Thérèse Calmettes, Anne‐Dominique Degryse, Antoine Dumoulin, Luc De Vries & Didier Cussac. (2016) Pharmacological evaluation of a series of smoothened antagonists in signaling pathways and after topical application in a depilated mouse model. Pharmacology Research & Perspectives 4:2.
Crossref
Crossref
Susanne Rehefeldt-Erne, Mirjam C. Nägeli, Nina Winterton, Lea Felderer, Lisa Weibel, Jürg Hafner & Reinhard Dummer. (2016) Nevoid Basal Cell Carcinoma Syndrome: Report from the Zurich Nevoid Basal Cell Carcinoma Syndrome Cohort. Dermatology 232:3, pages 285-292.
Crossref
Crossref
Yuji Shimizu, Tsuyoshi Ishii, Kazumasa Ogawa, Satoshi Sasaki, Hideki Matsui & Masaharu Nakayama. (2015) Biochemical characterization of smoothened receptor antagonists by binding kinetics against drug-resistant mutant. European Journal of Pharmacology 764, pages 220-227.
Crossref
Crossref
Nicole Basset-Seguin, Axel Hauschild, Jean-Jacques Grob, Rainer Kunstfeld, Brigitte Dréno, Laurent Mortier, Paolo A Ascierto, Lisa Licitra, Caroline Dutriaux, Luc Thomas, Thomas Jouary, Nicolas Meyer, Bernard Guillot, Reinhard Dummer, Kate Fife, D Scott Ernst, Sarah Williams, Alberto Fittipaldo, Ioannis Xynos & Johan Hansson. (2015) Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial. The Lancet Oncology 16:6, pages 729-736.
Crossref
Crossref
Michael R Migden, Alexander Guminski, Ralf Gutzmer, Luc Dirix, Karl D Lewis, Patrick Combemale, Robert M Herd, Ragini Kudchadkar, Uwe Trefzer, Sven Gogov, Celine Pallaud, Tingting Yi, Manisha Mone, Martin Kaatz, Carmen Loquai, Alexander J Stratigos, Hans-Joachim Schulze, Ruth Plummer, Anne Lynn S Chang, Frank Cornélis, John T Lear, Dalila Sellami & Reinhard Dummer. (2015) Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial. The Lancet Oncology 16:6, pages 716-728.
Crossref
Crossref
Atsushi Otsuka, Mitchell P. Levesque, Reinhard Dummer & Kenji Kabashima. (2015) Hedgehog signaling in basal cell carcinoma. Journal of Dermatological Science 78:2, pages 95-100.
Crossref
Crossref
B.A. AlDabagh & S.T. Arron. (2014) Advanced basal cell carcinoma: how rare is the diagnosis?. British Journal of Dermatology 171:5, pages 932-933.
Crossref
Crossref